Digoxin Prescription Emerges as Key Player in Enhancing Survival after Hybrid Stage 1 Palliation in infants: Study
In a groundbreaking development in pediatric cardiology, a recent study has unveiled the positive impact of digoxin prescription on the transplant-free interstage survival of infants with single-ventricle physiology following hybrid stage 1 palliation. The analysis found that for infants with single-ventricle physiology who underwent hybrid stage 1 palliation, the digoxin prescription at hospital discharge is linked to improved transplant-free interstage survival.
Take home points: Through the analysis of data from a multicenter clinical registry, infants with single-ventricle heart defects who received digoxin prescriptions at the time of hospital discharge after undergoing stage 1 hybrid palliation exhibited elevated transplant-free survival during the interstage period. These results align with prior studies involving the stage 1 Norwood operation, indicating that the proactive use of digoxin may be a reasonable approach during the interstage period for infants who have undergone the stage 1 hybrid palliation procedure.
Further reading: Reddy RK, Zyblewski SC, Chowdhury SM, et al. Association of Digoxin Use With Transplant-Free Interstage Survival in Infants Palliated With a Stage 1 Hybrid Procedure. J Am Heart Assoc. 2023;12(20):e029521. doi:10.1161/JAHA.123.029521
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd